Advertisement

Topics

Santarus Company Profile

18:02 EDT 20th September 2017 | BioPortfolio

We are a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians. Our current products are immediate-release formulations of omeprazole, a widely prescribed proton pump inhibitor, or PPI. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal, or GI, diseases and disorders. We currently market ZEGERID® (omeprazole/sodium bicarbonate) Capsules and ZEGERID (omeprazole/sodium bicarbonate) Powder for Oral Suspension. These products are the first and only immediate-release oral PPIs approved by the U.S. Food and Drug Administration, or FDA, for commercial sale in the U.S. (see Products for more information). ZEGERID Capsules and ZEGERID Powder for Oral Suspension are being marketed in the U.S. by a field sales force of over 500 sales representatives who promote ZEGERID products in the primary detail position. Our sales force presence includes approximately 210 of our own field sales representatives and 170 field sales representatives under a co-promotion agreement with Otsuka America Pharmaceutical, Inc. In addition, our field sales force presence increased in early 2007 with the addition of approximately 140 contract sales representatives from inVentiv Commercial Services, LLC. The ZEGERID sales force calls on approximately 26,000 gastroenterologists and primary care physicians who are among the highest prescribing U.S. physicians for PPIs. In 2006 we reported net product sales of approximately $46 million, compared to 2005 net product sales of $13.7 million. These sales results were accomplished with only nine months of capsules sales and ZEGERID Capsules have quickly become our primary product offering. Our stock trades on the NASDAQ Global Market under the symbol "SNTS".

Location

10590 West Ocean Air Drive
Suite 200
San Diego
CA
92130
United States of America

Contact

Phone: 858-314-5700
Fax: 858-314-5701
Email: contact@santarus.com


News Articles [1 Associated News Articles listed on BioPortfolio]

Depomed To Present At Jefferies 2013 Global Healthcare Conference

NEWARK, Calif., May 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New Y...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Cycloset [Santarus, Inc.]

These highlights do not include all the information needed to use CYCLOSET safely and effectively. See full prescribing information for CYCLOSET. CYCLOSET (bromocriptine mesylate) Tablets, oralInitial...

Zegerid® with magnesium hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide) [Santarus, Inc.]

ZEGERID® with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide)

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Santarus, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gas...

Santarus, Inc. and Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by phy...

Santarus, Inc. & Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by phy...

Santarus, Inc. and Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST™ (RHUCIN® in non-European territories) is a recombinant human C1 inh...

Depomed, Inc.

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products...

More Information about "Santarus" on BioPortfolio

We have published hundreds of Santarus news stories on BioPortfolio along with dozens of Santarus Clinical Trials and PubMed Articles about Santarus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Santarus Companies in our database. You can also find out about relevant Santarus Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record